An influence of the parathyroid hormone on metabolic processes in severe glucocorticoid osteoporosis

Sergey Zolotukhin, Hasan Aussie, Mykola Shpachenko, Yury Kryuk, Dmitry Pyrko

Abstract


The article contains data on the modelling of experimental glucocorticoid osteoporosis. Severe, moderate and mild osteoporoses were diagnosed by X-ray criteria. In order to assess degrees of metabolic disturbances in osteoporosis, 11 biochemical indices were reduced to a single scale of values with reference to the control level and studied. Teriparatide, injected subcutaneously at a dose of 5 mcg/kg, was used for the treatment. It was revealed, that Teriparatide inhibited the pathological process, which had already developed, and produced a restorative effect in osteoporosis. This kind of its action, synchronous with withdrawal of Prednisolon, reduced metabolic processes, eventually increasing the life-span of the rats with osteoporosis. Taking into account a positive influence of Teriparatide on metabolism, an effect of the stimulation of osteoblast activity in the drug action mechanism may be assumed. Hence, Teriparatide in glucocorticoid osteoporosis had an expressed therapeutic effect manifested by a reduction of metabolic disturbances and an increase in the life-span of the rats.

Keywords


glucocorticoid osteoporosis; Teriparatide

References


Беневоленская Л.И. Проблема остеопороза в современной медицине / Л.И. Беневоленская // Вестник РАМН. — 2003. — № 7. — С. 15–18.

Буфистова А.В. Прогнозирование тяжести течения глюкокортикоидного остеопороза(экспериментальное исследование) / А.В. Буфистова, С.Е. Золотухин, В.П. Коробов [и др.] // Загальна патологія та патологічна фізіологія. — 2006. — Т. 1, № 2. — Додаток А. — С. 64–74.

Ермоленко В.Н. Фосфорно-кальциевый обмен и почки // Нефрология: Руководство для врачей / [под ред. И.Е. Тареевой]. — М.: Медицина, 2000. — С. 62–75.

Кластер У. Нарушения минерального обмена и костного метаболизма: терапевтический справочник Вашингтонского университета / [под ред. М. Вудли и А. Уэлан]. — М.: Практика, 1995. — С. 502–601.

Климовицкий В.Г. Влияние гормонов щитовидной и паращитовидной желез на механизмы резорбции и формирования костной ткани при глюкокортикоидном остеопорозе (экспериментальное исследование) / В.Г. Климовицкий, С.Е. Золотухин, А.В. Буфистова [и др.] // Український морфологічний альманах. — 2005. — Т. 3, № 1. — С. 30–34.

Тесняк О.М. Медикаментозные методы лечения остеопороза / О.М. Тесняк // Ревматология. — 2005. — Т. 7, № 2. — С. 29–36.

Benson C.T. Teriparatide has no effect on the calcium-mediated pharmacodynamics of digoxin / C.T. Benson, J.R. Voelker // J. Clinical Pharmacology Therapy. — 2003. — V. 73. — P. 87–94.

Body J.J. A randomized double-blind triol compare the efficacy of teriparatide [recombinant human parathyroid hormone (1–34)] with alendronate in postmenopausal Women with osteoporosis / J.J. Body, G.A. Gaich, W.H. Scheele [et al.] // J. Clinical Endocrinology and Metabolism. — 2002. — V. 87. — P. 4528–4535.

Juppner H. A G-proteinlinked receptor for parathyroid hormone and parathyroidrelated peptide / H. Juppner, A.B. Abon-Samra,M. Freeman [et al.] // Science. — 1991. — V. 254. — P. 1024–1026.

Mosekilde Li. The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength-assessed in sexually nature, ovariectomized rat model / Li Mosekilde, C.C. Danielsen, C.H. Sogaard [et al.] // Bone. — 1995. — V. 16. — P. 223–230.

Sambrook Ph. Osteoporosis / Ph. Sambrook, C. Cooper // Lancet. — 2006. — T. 367. — P. 2010–2018.




DOI: https://doi.org/10.15674/0030-59872009145-48

Refbacks

  • There are currently no refbacks.


Copyright (c) 2014 Sergey Zolotukhin, Hasan Aussie, Mykola Shpachenko, Yury Kryuk, Dmitry Pyrko

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.